Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Hershman of Columbia University in New York, so this is not like a lot of studies where you find a statistically significant difference thats not clinically meaningful. In addition, the incidence of grade 3/4 neurotoxicity was 3.8% with ALC, much higher than the 0.5% seen with placebo
The coverage table: This is standard across all major insurers
Around the same time, I think you remember that all of pharma was interested in obesity in the early 90s, everyone wanted to do diabetes as well as obesity, but they were separate teams and they all wanted to do small molecules, but it just happens to be so that the best idea we could find at that time was actually GLP-1, because we actually had clinical data relatively early that GLP-1 was a really good candidate as a treatment for diabetes because of the glucose sensitivity of the actions
Melanotan is also linked with weight loss but has not been approved as a weight-loss aid by many worldwide healthcare systems
